Thursday, December 2, 2010

More on Recent Ghostwriting Allegations: A Crazy Theory

I have a somewhat off the wall theory to offer regarding the recent ghostwriting revelations/allegations from the New York Times:
http://brodyhooked.blogspot.com/2010/11/ghostwriting-from-journal-articles-to.html

Okay, in this crazy world of the medicine/Pharma interface, can anything really be off the wall?

Let's go back to the revelations from the recent round of ProPublica investigations of drug payments to docs:
http://brodyhooked.blogspot.com/2010/10/from-propublica-seamy-side-of-pharma.html

One of the things this drove home, though we had much evidence of it before, is that speakers' bureaus are basically bribe machines to reward high-prescribing physicians; the ability to speak coherently is much less of a qualification.

So what are we to make of the fact that (according to documents obtained by the Times) SmithKline Beecham paid muchos bucks to a medical communications company to ghostwrite a textbook that KOLs Drs. Charles nemeroff and Alan Schatzberg could sign on as authors, and the textbook was supposed to educate family docs about how to treat psychiatric illnesses, but only 10,000 copies were sold (vs. a family doc population in the US of about ten times that much)?

Let's ask-- supposing that that book contained information that SmithKline really wanted family docs to know, and that they judged the textbook a useful format by which to convey that information, what would they have done?

Answer--that's easy. The sales for the textbook would have been 100,000 not 10,000. All copies would have been bought by SmithKline. A SmithKline rep would have personally delivered a copy to each family doc in the US, as a gift from the company. The cost would have been chump change for a big drug firm.

So how do we account for the fact that only 10,000 were sold? How about the notion that SmithKline chose to handle KOLs Nemeroff and Schatzberg just like Dr. Big Prescriber up the road, but on a grander scale, given their presumably huge value to the industry as Shills Extraordinaire? Everyone knows that having a medical textbook to list on your CV as an author is a plum perk for an academic physician. So SmithKline ultimately didn't care if no one bought the book and if no family doc ever read a page of it--just like they really don't care who or how many attend the drug talk given by the paid speaker, so long as the speaker gets his bribe to put in his pocket and know's there's more where that came from if he keeps that prescription mill going. (The Times did not reveal specifically what Drs. Nemeroff and Schatzberg were paid, personally, for their role in putting their names on the cover of this book; but past behavior would cause us to doubt that they would have participated without being offered a nice honorarium--in addition to the honorific of having a major publication to list on their CVs.)

Like I say, maybe I've finally gone off the deep end. This business will do that to you.

6 comments:

Lori said...

Interesting, but I'm trying to remember the rules of what sales reps could hand out back in 1999. If the book contained off-label information about any of SKB's products, I'm not sure that they could freely hand them out, at least not the sales force. The book may have had to come from the clinical side of the business and/or in response to an unsolicited request from a doctor.

It would be interesting to know who bought those 10K books - individuals or a bulk purchase by SKB? If the latter, how and to whom did they distribute them?

shocked... shocked, I say said...

@ Lori: From the original NYT report:"The book sold about 26,000 copies, including 10,000 bought by SmithKline Beecham for American family doctors and 10,000 purchased by the Dutch pharmaceutical company Organon... The authors together received a 15 percent royalty of the $120,000 sales, or about $18,000..."

So, SmithKline Beecham distributed 10,000 copies, and Organon did the same. Does anyone want to lay odds on Nemeroff and Schatzberg having had a side agreement with Organon? For a consideration, no doubt. Schatzberg more than Nemeroff is known as a KOL for Organon's antidepressant drug Remeron (mirtazapine).

1boringoldman said...

@Lori
I'm not sure that the book [Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care] is weighted towards SKB or Organon products. It looks like they played it straight, at least in the limited Google book version. However, giving a Primary Care doc a $78.00 book to look up Psyc meds and doses encourages them to prescribe for Psyc Sx, and the fact that the SKB [or Organon] rep gave them the book would go a long way in influencing drug choices. As the Preface to that book says,"about 60% of patients with psychiatric disorder are identified and receive treatment in a primary care setting." It's their biggest market. 20,000 grateful Primary Care physicians feeling more comfortable prescribing [non-generic] psychoactive medications could be worth a lot to either company.

It's hardly paranoia to say that with these two guys, there's always an angle. It's just a question of figuring out what it is...

Anonymous said...

I love conspiracy theories. Don't you find it strange that as Psychiatry has been overtaken by the likes of Charlie and Alan, the DSM-V Task Force is trying to do away with narcissistic and antisocial personality disorders as diagnoses? Just asking.

stock trading said...

It looks like they played it straight, at least in the limited Google book version.This link might be more helpful.

Michael S. Altus, PhD, ELS said...

I contacted the Press Office of the American Psychiatric Association with questions about the extent of sales about the book, “Recognition and Treatment of Psychiatric Disorders.”
~~~~~~~~~~~~~~~

Subject: Follow-up from Michael S. Altus PhD, ELS, about sales of “Recognition and Treatment of Psychiatric Disorders”
Date: Fri, 03 Dec 2010
From: Michael S. Altus, PhD, ELS
To: Staff Member, Press Office of the American Psychiatric Association

(Staff Member),

Thank you for your telephone call in response to my query about sales of a book “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care” by Charles Nemeroff, MD, and Alan F. Schatzberg, MD, published by American Psychiatric Publishing, Inc., in 1999. I want to find out the extent of the book’s sales.

As you know, The New York Times had an article, “Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say,” by Duff Wilson, published on November 29, 2010. The article is available at (http://tinyurl.com/3azgyap).

According to the article, Ron McMillen, chief executive of American Psychiatric Publishing, which published the book, explained that the book sold about 26,000 copies, including 10,000 bought by SmithKline Beecham and 10,000 bought by Organon. The authors together received a 15 percent royalty of the $120,000 sales, or about $18,000.

If book sales were $120,000, and 26,000 copies were sold, then the book sold for only about $4.65. Could it be that total sales were $1,200,000, for $46.50 per book? Or perhaps only 2,600 books were sold, with only 1,000 to each of the 2 pharmaceutical companies?

According to a book review by Dr. Robert Cancro in Am J Psychiatry 158:331, February 2001 (http://tinyurl.com/277pcnv), the book's price was $35.00.

I ask that you check on the numbers of copies sold to the drug companies and others; the dollar amounts of sales and of royalties; and the price of the book.

As I explained, I inquire on my own behalf. I am a freelance medical writer-editor who is deeply concerned about ethics in preparing articles for publication. For example, I refer to AMWA Ethics FAQs (www.amwa.org/default.asp?id=466), which I wrote for the American Medical Writers Association.

Thank you again for your consideration.

Michael

Michael S. Altus, PhD, ELS
Intensive Care Communications, Inc.®
Biomedical Writing and Editing
altus@intensivecarecomm.com
www.intensivecarecomm.com

~~~~~~~~~~~~~~~
Subject: RE: Follow-up from Michael S. Altus PhD, ELS. about sales of...
Date: Fri, 3 Dec 2010
From: Staff Member, Press Office of the American Psychiatric Association
To: Michael S. Altus, PhD, ELS

Hi Michael,
Haven't forgotten you! I have some requests out to get the information you need. Since it’s Friday we may not hear back today. Is it ok if we touch base on Monday??

(Staff Member)
~~~~~~~~~~~~~~~


Subject: Re: Follow-up from Michael S. Altus PhD, ELS. about sales of “Recognition and Treatment of Psychiatric Disorders'
Date: Mon, 06 Dec 2010
From: Michael S. Altus, PhD, ELS
To: Staff Member, Press Office of the American Psychiatric Association

(Staff Member),

Yes, I can wait.

Meanwhile, I have another question: When did American Psychiatric Publishing first become aware that Drs. Nemeroff and Schatzberg had relationships with Scientific Therapeutics Information and with SmithKline Beecham in relationship to development of the book, “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care"?

Many thanks again for your help.

Michael

Michael S. Altus, PhD, ELS
Intensive Care Communications, Inc.®
Biomedical Writing and Editing
altus@intensivecarecomm.com